NCT07216066RecruitingPhase 1
First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson’s Disease (PD)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 Sept 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 30 Jul 2025
- Start date
- 20 Nov 2025
- Lead sponsor
- Regeneron Pharmaceuticals Inc.
- Diseases
- Parkinson disease
- NCT number
- NCT07216066
- EU CT number
- 2025-521431-37-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 25
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZ Leuven Coordinator of this site? Confirm its status | Leuven | Belgium | Not yet recruiting |
| Centre for Human Drug Research Coordinator of this site? Confirm its status | Leiden | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.